With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

Regeneron Pharmaceuticals and Sanofi are collaborating on a Phase 4 clinical study titled ‘A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Dupilumab on Airway ...

News provided by Regeneron Pharmaceuticals, Inc. Feb 16, 2024, 12:59 AM ET Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the ...